This study is testing a new way to deliver radiation therapy called daily adaptive external beam radiation therapy for people with pancreatic cancer that is borderline resectable (meaning it's difficult to remove with surgery), locally advanced, or medically inoperable. The goal is to see if this specialized radiation treatment can reduce severe side effects in the stomach and intestines (GI toxicities). You may be able to join if you are 18 or older, have a good performance status (ECOG 0-1), and have already received at least two months of chemotherapy. The main way we'll know if the treatment is successful is by tracking severe GI toxicities within 90 days of starting treatment. The current recruitment status is unclear.

Study design

This is a single-arm study, meaning all participants receive the same treatment. It plans to enroll 134 participants.

What's involved

You would receive daily adaptive external beam radiation therapy. You must have completed at least two months of chemotherapy before starting this treatment.

Compensation

Not stated in the trial record.

Follow-up

The study will track acute GI toxicities for 90 days from the start of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.